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ABSTRACT: Background. Head and neck squamous cell carcinomas
(HNSCCs) have devastating morbidity rates with mortality mainly
because of metastasis.
Methods. Multiplex enzyme-linked immunosorbent assay (ELISA)
to assay a variety of cytokine levels secreted by a panel of stage-
specific and anatomic site-specific primary, and recurrent and metastatic
University of Michigan-HNSCC cell lines over a 72-hour time course.
Results. Conditioned medium from metastatic or recurrent HNSCC
showed significantly higher amounts of interleukin (IL)-6, IL-6 receptor,
tumor growth factor-beta (TGF-b) and vascular endothelial growth factor
(VEGF) than nonmetastatic cells or normal oral keratinocytes. Tumor
necrosis factor (TNF) was only secreted by stage IV, metastatic, or
recurrence-derived cell lines.
Conclusion. The cytokine profile of cultured HNSCC cells suggests that
high levels of IL-6 and IL-6R, TGF-b, and VEGF are significantly related
with their metastatogenic potential and provide rationale for determining
if serum testing for a combination of these 4 soluble factors could be of
predictive value for the HNSCC tumor progression and clinical outcome.
VC 2013 Wiley Periodicals, Inc. Head Neck 35: 1542–1550, 2013
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INTRODUCTION
Head and neck squamous cell carcinomas (HNSCCs) are
associated with poor clinical outcome and mortality rates
among the highest of all carcinomas.1 Among the
HNSCC, oral cancer is statistically shown to be the most
devastating with high mortality rates because of their
high metastatic potential.1 The extent of metastatic poten-
tial is dependent on the tumor extracellular environment
with intercellular signaling by cytokines thought to be
one of the critical components. Cytokines can have auto-
crine effects promoting tumor cell growth as well as para-
crine effects on myeloid, lymphoid, and endothelial cells
enhancing metastatogenesis.2–7 Thus, certain carcinomas
recruit vascular endothelial growth factor (VEGF) recep-
tor 1–positive hematopoietic progenitors to the premeta-
static niche by secreting VEGF-1.2–5 Tumor growth
factor-beta (TGF-b) can promote tumor cell proliferation
through an autocrine effect.2–5 Elevated serum levels of
cytokines such as interleukin (IL)-6 that are involved in
inflammatory processes are often indicative of tumor pro-
liferation and a poor clinical prognosis and outcome.2–8
In the current study, we compared the levels of cytokines
secreted by a panel of cell lines established by our group
(University of Michigan-squamous cell carcinoma [UM-
SCC] 10A, 10B, 11A, 11B, 22A, 22B, 12, 6, 103, 14A,
14B, and 47).9,10 See Table 1 in Lin et al10 with the Ameri-
can Type Culture Collection clones SCC4 (nonmetastatic),
Cal27 (metastatic), and normal oral keratinocytes (NOKs)
at multiple time points over a time course of 72 hours. Our
goal was to investigate the cytokine signature of cultured
HNSCC and to assess the plausibility of using cytokine
profiles as a possible diagnostic and prognostic tool.
The cytokines tested were ILs 2, 3, 4, 7, and 6, and its
receptor, tumor necrosis factor (TNF) and its receptor,
interferon (IFN) alpha and gamma, VEGF, and TGF-b.
We postulate that differences in cytokine profiles that are
associated with aggressive tumor characteristics could be
used to our advantage clinically. Cytokine concentration
assays are easy and fairly inexpensive to perform, and
could be the basis of a quick test of predictive value for
the tumor progression and clinical outcome in patients
who present symptoms of head and neck cancer.
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MATERIALS AND METHODS
Cell lines and cell culture
The cell lines used in this study were established by
our group.9 Table 1 summarizes their origin, staging, and
treatment subjected to before derivation. We also used
American Type Culture Collection (Manassas, VA) clones
SCC4 (CRL-1624) and Cal 27 (CRL-2095). All carcinoma
cell lines were cultured in Dulbecco modified Eagle’s me-
dium (Invitrogen, Carlsbad, CA), 1% nonessential amino
acids, 100X (Invitrogen), and 1% penicillin-streptomycin,
100X (Invitrogen). The flasks were placed in 37C incu-
bators with 5% carbon dioxide. They were passaged at a
split ratio of 1:3 to 1:6. The cell lines were periodically
monitored for mycoplasma contamination and tested neg-
ative. The cell lines were genotyped to rule out cross-con-
tamination and to confirm their identity, and their mor-
phologies were regularly examined. Human NOKs were
obtained from the ScienCell Research Laboratories
(Carlsbad, CA; catalog number: #2610) and grown in ba-
sal keratinocytes growth media for the routine serum-free
culture of normal human keratinocytes in accord with the
manufacturer’s instructions (Lonza, Walkersville, MD)
supplemented with hydrocortisone, insulin (bovine),
human epithelial growth factor, and bovine pituitary
extract.
Supernatants collection
Cells were passaged at different densities to achieve
70% confluence at varying time periods (4, 8, 24, 48, and
72 hours). Supernatants were collected in each of these
time points and stored in at 80C until they could all be
processed together. Supernatants collection was preceded
by 24 hours of serum-free culture of the HNSCC cell
lines. Protease inhibitors (Complete Mini Kit with EDTA,
Roche, San Francisco, CA) were added to the thawed
supernatants that were then concentrated by centrifugation
in a Beckman swing-bucket table-top centrifuge at 3750
rpm in Amicon Ultra-15 filter tubes (Millipore, Billerica,
MA) that had been passivated overnight with 0.1%
Tween-20 in accord with the manufacturer’s instructions.
Concentration coefficients were recorded and all cytokine
values are adjusted according to concentration factors.
Protease Inhibitors (SIGMA) leupeptin, pepstatin, and
aprotinin, as well as phenylmethylsulfonyl fluoride and
EDTA were then added to the concentrates.
Multiplex enzyme-linked immunosorbent assay
Multiplex ELISA was outsourced to the University of
Maryland Cytokine Core and was carried out using a
Millipore Kit (Upstate Biotechnologies, New York, NY).
Appropriate reagents were used and all the procedures
were followed in accord with the manufacturer’s instruc-
tions. The cytokines tested were ILs 2, 3, 4, 7, and 6, and
its receptor, TNF and its receptor, IFN alpha and gamma,
VEGF, and TGF-b. Standard curves were used and con-
trols were run for each cytokine tested. Triplicate tests
were carried out for each sample. The plates were read
using Luminex technology and I.S. software. The final
concentrations (expressed in pg/mL) were calculated
using Upstate multiplexing software and were adjusted so
they are statistically comparable.
Statistical analysis
Triplicate tests were carried out for each sample. Val-
ues for repeats have been averaged and SD has been
added to the reported means. We performed a statistical
analysis of all the samples including all time points using
PASW Statistics 17 software. We have used the 2 most
popular nonparametric tests of central tendency, the Man-
n–Whitney and Wilcoxon tests; Table 2 summarizes the
means and SDs for all the time points tested. Statistical
values are listed for each comparison and p values < .05
were considered significant.
TABLE 1. Cell lines and their characteristics.
Cell line Grade/differentiation Stage Specimen site Type of lesion Primary site Previous treatment
UM-SCC 10A Moderate to well III True vocal cord Primary Vocal cord None
UM-SCC 10B Moderate to well III Lymph node Metastasis Larynx Surgery
UM-SCC 11A IV Epiglottis Primary Epiglottis None
UM-SCC 11B IV Supraglottic larynx Persistent Larynx Chemotherapy
UM-SCC 12 Moderately well III Larynx Recurrence Larynx Surgery
UM-SCC 22A Moderate III Hypopharynx Primary Hypopharynx None
UM-SCC 22B Moderate III Lymph node Metastasis Hypopharynx None
UM-SCC 14A Poorly to Moderate I Floor of the mouth Recurrence Floor of the mouth Surgery
UM-SCC 14B Poorly differentiated I Floor of the mouth Recurrence Floor of the mouth Surgery, radiation therapy
UM-SCC 47 Moderately well III Tongue Primary Lateral tongue None
CAL27 Poorly differentiated I Tongue Primary Tongue Radiotherapy, surgery,
chemotherapy
SCC4 Moderate III Tongue Primary Middle of tongue Radiotherapy, chemotherapy
UM-SCC 6 Poorly to Moderate II Tongue Primary Base of tongue None
UM-SCC 103 Well IV Tongue Primary Right lateral tongue None
NOK - - - - - -
Abbreviation: UM-SCC, University of Michigan-squamous cell carcinoma.
Note: Table indicates the cell lines used in this study and their complete information: the degree of differentiation as shown by cytology (grade/differentiation), the stage of the cancer at the time of
cell line derivation (stage), the head and neck site of the biopsy (specimen site), whether the biopsy was of primary, recurrent or metastatic lesion (type of lesion), what the primary site of occur-
rence had been (primary site), and the treatment received by the patient before cell line derivation (previous treatment).
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RESULTS
Head and neck carcinoma versus normal oral
keratinocyte---overview
HNSCC cell lines (their complete information is sum-
marized in Table 1) and NOK cytokine concentrations have
been measured (pg/mL) for various time periods of incuba-
tion (4, 8, 24, 48, and 72 hours). The cytokine expression
of the HNSCC cell lines was compared to NOK. The
results of this comparison were consistent for all the time
points analyzed; Figures 1 to 4 highlight the conclusions by
analysis of cytokine values corresponding to the 48-hour
time point for each of the cell lines shown. Despite the vari-
ous growth factors contained in the keratinocytes growth
media used for the routine serum-free culture of normal
human keratinocytes, the values measured in NOK for all
the cytokines tested were undetectable or low.
The Mann–Whitney and Wilcoxon test results as an aver-
age for all the time points tested are summarized in Table 2
(gray highlights the results of the statistically significant).
Within the tested panel, only IL-6, IL-6 receptor, VEGF,
and TGF-b showed significant differences in expression
between HNSCC and NOK. By normalizing the levels of
cytokine expression of each cell line versus the NOK, we
found that there are also differences in the expression of
these cytokines between oral cancer originated cell lines
(UM-SCC 14A, 14B, 6, 47, 103, SCC4, and Cal 27) and
non-oral cancer cell lines (UM-SCC 10A, 10B, 11A, 11B,
12, 22A, and 22B). Finally, a difference was found between
cell lines established from a primary tumor site and its met-
astatic relative; conditioned medium of metastatic cell lines
showed significantly higher amounts of IL-6, IL-6 receptor,
TGF-b, and VEGF than conditioned medium from nonme-
tastatic cells or oral keratinocytes. No significant levels of
IFN-gamma or IL-2, 3, 4, and 7 were measured. Finally,
TNF-alpha was only secreted by stage IV metastatic and re-
currence-derived cells.
Briefly, the statistical analysis showed that VEGF levels
are the best indicators for all comparisons run. VEGF val-
ues were higher for non-oral as opposed to oral cancers, for
cell lines derived from advanced as opposed to early-stage
cancers, and for lines from cancers with positive as opposed
to negative lymph node metastases (Table 2). VEGF, IL-6,
and IL-6R activity was very high in head and neck cancer
cell lines as opposed to normal keratinocytes (Figure 1A)
and were detectable from cell lines from even early-stage
oral and non-oral primary cancer sites. VEGF values
seemed to differentiate between cell lines from early or late
stage tumors in both oral and non-oral cancers.
TGF-b expression for the cancer cell lines was over 3
times higher than NOK. A maximum threshold has been
detected in the highest expressing stage IV tumor-derived
cells, UM-SCC11B, in which TGF-b activity was about
10 times that of NOK. Interestingly, TGF-b expression
was significantly higher in supernatants from late-stage
carcinoma cell lines, particularly in those that originated
from the oral cavity. Values increased between stage IV
primary oral cavity cell lines with distant metastasis and
the stage IV primary oral cavity cell lines without distant
metastasis. A schematic view of the data summarized in
Table 2 and discussed above is presented in Figure 1A to
D (values are expressed in picograms/mL).TA
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Early stage versus late stage
Our analysis indicated that supernatants from HNSCC
cell lines established from tumors at a late stage (III–IV)
have levels of IL-6, IL-6R, and VEGF that are signifi-
cantly higher than the levels of the same cytokines in
supernatants from cell lines of tumors at early stages
(I–II; Figure 1B). TGF-b was also higher in late-stage tu-
mor cell lines, although the difference was not significant
(Table 2 and Figure 1B).
Non-oral versus oral carcinomas
The mean expression of IL-6R, VEGF, and TGF-b was
significantly higher in non-oral than in oral SCC (OSCC)
cell lines, whereas IL-6 levels, although not statistically
significant, were found to be twice as high in non-oral
cell lines as the levels in OSCC (Table 2 and Figure 1C).
Although this is consistent for all time points analyzed,
only the differences at the 48-hour time period are illus-
trated for simplicity.
Metastatic versus nonmetastatic head and neck
squamous cell carcioma
Our data indicated that IL-6, IL-6R, and VEGF were
significantly higher in supernatants from HNSCC cell
lines derived from patients with lymph node metastasis
than in those with negative lymph node metastasis at all
the analyzed time points. In contrast, there was no signifi-
cant difference for TGF-b (Table 2). Our analysis also
found a difference between metastatic (UM-SCC 10B,
11B, 14B, and 22B) and nonmetastatic cell lines (UM-
SCC 10A, 11A, 22A, 47, Cal 27, and SCC4), which is
illustrated in Figure 1D.
IL-6 expression was higher for metastatic cell lines than
for the primary site cell lines. VEGF was also significantly
higher for metastatic HNSCC. IL-6R expression in meta-
static HNSCC was lower than the expression observed in
primary site cell lines, whereas TGF-b expression was sig-
nificantly higher in stage IV primary oral cavity cell lines
with distant metastasis than the stage IV primary oral cav-
ity cell lines without distant metastasis.
FIGURE 1. Mean cytokine levels in head and neck squamous cell carcinomas (HNSCCs). Cytokine concentrations subjected to statistical analysis
as described in the Methods section. Although the results of our analysis were consistent for all the time points analyzed, the figure highlights the
conclusions by analysis of cytokine values corresponding to the 48-hour time point for each of the cell lines shown. Values are expressed in pg/
mL. Basis for comparison included: (A) cytokine values for HNSCC cell lines as compared to normal oral keratinocytes (NOKs); (B) staging (late ¼
stages III and IV vs early ¼ stages I and II); (C) oral vs non-oral origin of tumors; and (D) whether lymph node metastasis was present (Nþ) or not
(N0) at the time of cell line derivation. Among the cytokines tested, interleukin (IL)-6, IL-6R, vascular endothelial growth factor (VEGF), and
transforming growth factor-beta (TGF-b) show significant differences in HNSCC versus NOK. The increase in VEGF expression was the most
notable for late-stage and metastatic HNSCC.
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Interleukin-6/interleukin-6R ratio
IL-6R levels were many fold higher when compared
with the control NOK levels (Figure 2). It is notable,
however, that the non-oral cell lines with the latest stag-
ing and the highest IL-6 (Figure 2A and D) concentration
FIGURE 2. Interleukin (IL)-6, IL-6R, and their ratio values in head and neck squamous cell carcinoma (HNSCC) supernatants (normalized to normal
oral keratinocytes [NOKs]). IL-6 and IL-6R activities reported for the 48-hour time point of each analyzed cell line were averaged and the mean and
SD were divided by corresponding NOK values. Values are expressed in pg/mL. The graphs were generated using Microsoft Excel. IL-6 values used
for graphs shown in (A) and (D) were divided by IL-6R values (shown in graphs B and E) to calculate the IL-6/IL-6R ratio (C, F). Lines are used in the
graphs to connect values for cell lines originating from the same patient at progressive stages of the cancer, for example, University of Michigan-
squamous cell carcinoma (UM-SCC10A) and 10B. These illustrate a trend for increase or decrease with cancer progression (discussed in Results
and Discussion sections).
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also had greatly reduced levels of IL-6R (Figure 2B and
E). Overall, non-oral cell lines of stage III and oral can-
cer-derived cell lines of stage IV show a ratio of IL-6/IL-
6R that is lower than that of NOK, which was exactly
equal to 1 (Figure 2C and F). In contrast, stage IV non-
oral cancer cell lines 11A and 11B had 3 orders of mag-
nitude higher IL-6R expression than NOK (Figure 2C).
With the exception of values for stage IV cell lines, IL-6
values and IL-6/IL-6R ratios tend to increase during the
progression of the tumor from primary to recurrence/me-
tastasis, as is demonstrated by the rising slope of the line
connecting the value of primary versus recurrent tumor/
metastasis illustrated in Figure 2A, C, D, and F. The
maintenance of the physiologic phenotype may be de-
pendent on the maintenance of the ratio between the cyto-
kine and its receptor.
Head and neck squamous cell carcinoma versus normal
oral keratinocyte---interleukin-6, interleukin-6R,
vascular endothelial growth factor, and transforming
growth factor-beta
When compared with NOK, both non-oral-derived and
oral-origin-derived cell lines had concentrations of IL-6,
IL-6R (Figure 2A, B, D, and E), and VEGF (Figure 3B
and D) that were orders of magnitude higher than the val-
ues for NOK. TGF-b, although high in absolute value
(expressed in picograms/mL), was slightly higher in
HNSCC when compared with NOK (Figure 3A and C).
Head and neck squamous cell carcinoma versus normal
oral keratinocyte---tumor necrosis factor
An interesting trend was the higher expression of TNF
in cell lines of late stage in both non-oral and oral-
derived cell lines (Figure 4A and B). No TNF was detect-
able in NOK cells, therefore, the results shown in Figure
4 could not be normalized for NOK expression.
DISCUSSION
The goal of the current study was to investigate the
cytokine signature in cell line supernatants from HNSCC
and to provide rationale for use of cytokine profiles as
possible diagnostic and prognostic clinical tools. Head
and neck cancers are very immunogenic cancers, and are
often heavily infiltrated by lymphocytes, macrophages,
neutrophils, and dendritic cells.1 Chronic inflammatory
processes including cancer have been associated with
deregulated expressions of cytokines.11 Elevated serum
levels of cytokines that assist those inflammatory proc-
esses like IL-6 are often indicative of tumor proliferation
and a poor clinical prognosis and outcome.2–8 IL-6 is a
pleiotropic cytokine that is secreted by various cell types
in the body including fibroblasts, macrophages, lympho-
cytes, and activated keratinocytes.12 It has been identified
FIGURE 3. Transforming growth factor-beta (TGF-b) and vascular endothelial growth factor (VEGF) values in head and neck squamous cell
carcinoma (HNSCC) supernatants (normalized to normal oral keratinocytes [NOKs]). TGF-b (A, C) and VEGF (B, D) activities reported for the 48-hour
time point of each cell line illustrated were averaged and the mean and SD were divided by corresponding NOK values and graphed using
Microsoft Excel. Values are expressed in pg/mL.
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as a key regulator of a cytokine network responsible for
the progression of squamous cell skin carcinoma; IL-6
expression has been found to be upregulated when the tu-
mor progressed from a benign to a highly malignant
state.13 Our finding that IL-6 was higher in HNSCC cell
lines when compared with NOK by 4, 5, or 6 orders of
magnitude, is a strong indicator that IL-6 is significantly
involved in head and neck carcinoma. Accordingly, IL-6
expression was greater in cell lines derived from meta-
static HNSCC than in HNSCC established from nonmeta-
static primary site tumors suggesting that IL-6 may be
indicative of the metastatic potential of head and neck
cancer. IL-6 was also significantly higher in SCCs
derived from tumors diagnosed with high/late staging
when compared with SCCs established from early-stage
tumors, suggesting that IL-6 increases in concentration
when the tumor stage advances.
IL-6 is a key mediator of a complex cytokine network
heavily involved in signaling pathways. It binds to IL-6R
and then associates with gp130 receptors. The complex
becomes active and it triggers 3 main signaling pathways:
the JAK/STAT, the MAP kinase, and the PI3-kinase/Akt
pathway.14,15 Because IL-6R binds IL-6, it is, to some
extent, complementary to IL-6 and is present in relatively
high concentrations when IL-6 is upregulated. Our study
shows that IL-6R expression is elevated in the superna-
tants from head and neck cancer cell lines, whereas NOK
registered very low values of IL-6R. IL-6 and its receptor
were high in concentration in OSCC, which is in agree-
ment with another recent study that focused exclusively
on IL-6 and IL-6R expression in oral cancers.16 IL-6R
expression in late-stage tumors was higher than in early-
stage carcinomas. We still do not fully understand the
effects of IL-6 and IL-6R on cancer. Certain studies have
led to speculation that IL-6R might have binding partners
that are different that IL-6, such as a novel synthetic pep-
tide, S7, which is known to inhibit VEGF.17,18
Interestingly, our data also show that, overall, IL-6R
has higher expression levels in non-oral carcinomas than
the oral ones. In addition, in the oral-derived cancer cell
lines, we also noticed an increase in its secretion depend-
ent on staging, suggesting that IL-6 overproduction that
mirror tumor progression is mostly in its free unbound
form, which may be indicative for the poorer clinical out-
come of oral cavity cancers as opposed to other head and
neck carcinomas. However, opposing trends are seen with
staging for the IL-6/IL-6R ratio for non-oral versus oral
HNSCCs; for instance, the stage IV non-oral HNSCC
cells 11A and 11B show much lower expression of IL-6R
than stage III HNSCCs. As a consequence, the IL-6/IL-
6R ratio is 3 orders of magnitude higher in stage IV non-
oral HNSCC compared to NOK. When the cytokine is in
vast excess to its receptor, it may not have a significant
autocrine effect on proliferation, but it may potentiate the
local inflammatory response that facilitates invasion and
metastasis. Although oral cancer is known to be more
FIGURE 4. Tumor necrosis factor (TNF) values in head and neck squamous cell carcinoma (HNSCC) supernatants (not normalized to normal oral
keratinocytes [NOKs]). TNF activities reported for the 48-hour time point of each cell line were averaged and the mean and SD were graphed using
Microsoft Excel.
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aggressive than non-oral cancer, there may be other fac-
tors that explain the differences between the 2 categories
such as VEGF-independent tumor angiogenesis mediated
via either the intracellular IL-6 or platelet-derived growth
factor, or the chemokines that contain the glutamine-leu-
cin-arginine motif with IL-8 being one of their
representatives.19–21
It is notable that among oral cancer cell lines, IL-6R
was lowest in a cell line derived from a recurrent tumor
(UM-SCC 14B) but the IL-6/IL-6R ratio was very high
for this cell line. With the exception of values for stage
IV cell lines, IL-6 values and IL-6/IL-6R ratios tend to
increase during the progression of the tumor from primary
to recurrence/metastasis (as is demonstrated by the rising
slope of the line connecting the value of primary versus
recurrent tumor/metastasis illustrated in Figure 2A, C, D,
and F). The IL-6/IL-6R ratios are therefore strategic
determinants of tumorigenesis because they are always
present at high levels in HNSCC when compared with
normal tissue, regardless of the primary site or stage, and
their levels may also be a determinant of lymph node
metastasis.
In various types of cancer, IL-6 is either a direct or an
indirect stimulant of the release of inflammatory and
angiogenic factors, such as IL-8, granulocyte-macrophage
colony-stimulating factor, VEGF, and MCP-1. In cervical
cancer, IL-6 can induce angiogenesis indirectly through
the release of VEGF.22 The combination of IL-6 and IL-
6R was shown to increase VEGF production in fibroblast-
like synovial cells from patients with rheumatoid arthritis,
whereas IL-6 by itself did not.23 In our study, VEGF fol-
lows the trends of IL-6 expression supporting the idea of
VEGF dependence on IL-6 (illustrated in Figure 1).
VEGF has been shown to promote lymphogenesis, angio-
genesis, and vascular permeability in cancer.24,25 Further-
more, our data indicate that VEGF values arise as the dif-
ferentiating factor between early and late stage tumors in
both oral and non-oral cancer (summarized in Table 1).
To our knowledge, there are no other studies evaluating
the cytokine levels of expression at multiple time points.
The current study analyzes 5 different time points over
72-hour period with consistent results, confirming the sta-
bility of the increase noted in the cytokines expression
levels and the reliability of multiplex ELISA as a highly
sensitive method of detection. Our data indicate that IL-6,
IL-6R, and VEGF were significantly higher in superna-
tants from HNSCC cell lines derived from patients with
lymph node metastasis than in those with negative lymph
node metastasis at all the analyzed time points, confirm-
ing the plausibility of using cytokine profiling as a possi-
ble diagnostic tool of HNSCC metastatic potential.
TGF-b acts as an antiproliferative agent in normal cells
in the body. In cancer, some of the components of the
TGF-b signaling pathway may become mutated, resulting
in a loss of TGF-b function in the cancer cells. Conse-
quently, TGF-b starts acting on nearby stromal, immune,
and endothelial cells. The effect may be harmful to
patients with cancer, as it suppresses the immune system
and induces angiogenesis.26 Our data indicate that TGF-b
expression was 3 times greater in head and neck cancer
cell line supernatants than in NOK, which is in agreement
with previous studies done on TGF-b in different types of
cancer. Given the significant amounts of the protein
secreted by normal cells, small-fold differences may have
significant long-term effects in tumor growth. Increased
stage and aggressiveness give rise to higher TGF-b levels
with a maximum threshold reached in the highest express-
ing cell line, the stage IV non-oral recurrent UM-SCC
11B, in which TGF-b activity was about 10 times that of
NOK.
TNF is not expressed in NOK or most HNSCC cell
lines except in the 4 late-stage cell lines, with the highest
values correlating to the most advanced stage. In a diag-
nostic implementation of our results, TNF expression
would be a late-stage determinant.
Although these results are exciting, they are based on
cell lines and further clinical or preclinical studies are
warranted to fully verify these hypotheses. Previous stud-
ies supported by the University of Michigan Head and
Neck SPORE have reported independently VEGF and IL-
6 detected in pretreatment serum as valuable biomarkers
for predicting recurrence and overall survival in patients
with HNSCC, thus indicative of tumor proliferation and a
poor clinical prognosis and outcome.6,8 Further develop-
ment of multiple cytokine profiling will require a larger
statistical sample of sera from patients with oral, head
and neck squamous cell carcinoma, assigning threshold
values and designing a test for clinical application. Our
results suggest that the serum cytokine expression profile
in head and neck cancer should be explored as a potential
clinical test that is simple to perform and inexpensive to
complete. The cytokine release profiles of HNSCC cell
lines with high levels of IL-6 and IL-6R together with
VEGF expression may characterize their relative meta-
static potential. This work also suggests that TGF-b and
TNF testing might be useful for the categorization of late
stage non-oral origin cancers. Thus, a combination test of
these various soluble factors may provide a stronger pre-
dictive value for the HNSCC tumor progression and clini-
cal outcome.
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